Connecting Cancer Genomics to Therapies & Trials
Clinicians and researchers need timely, data-driven decisions. Genomenon’s Cancer Knowledgbase bridges cancer genomics research and clinical care by linking genetic variants with therapies, trials and evidence - empowering faster, more confident decisions and advancing precision medicine.
CKB is a dynamic digital resource for interpreting even the most complex cancer genomic profiles. Used by thousands of clinicians and researchers across the globe, CKB saves time and finds valuable information that connects cancer variants to therapies and clinical trials.Genomic data is growing rapidly, but finding clinically relevant insights remains difficult. The complexity and inconsistency across resources slow down diagnosis and limit the potential of precision medicine.
In May of 2024, CKB became part of Genomenon. With the addition of CKB, Genomenon can provide an unprecedented understanding of the genome, with insights covering both germline and somatic variants, furthering its lead in the race to curate the genome.
For translational and clinical researchers, CKB provides thousands of literature citations, FDA drug labels, and clinical trials relative to a tumor’s genomic mutation or profile, resulting in a clear and up-to-date picture of discoveries and active developments for various biomarkers.
Identify new drugs and combinations of drugs that are currently being tested preclinically.
Although these therapies may not have made it to clinical trials, they may promise new options for future clinical development.
Identify possible resistance variants.
Sometimes a variant is present in a clinical sample following progressive disease, but is it driving the resistance? Using a controlled cell line expressing a presumed resistance variant and then assessing the drug resistance level can help confirm whether the variant may be predicted to cause resistance to a drug.
Identify resistance mechanisms for drug development.
If you are developing a new drug, knowing the commonly observed resistance variants that could be relevant for development may be helpful.
CKB can help increase clinician confidence in the completeness and accuracy of the information related to the patient’s tumor genomic profile, ensuring the best-informed clinical decision is made for a patient.
Reduce Turnaround Time
View & interpret variant information instantly, minimizing the need for additional research.
Unlock therapeutic interventions
Identify the best treatment for your patient from drug approvals to clinical trials – with ease.
Supercharge your team of experts
Access premium curated content, updated daily by our team of PhD scientists.
CKB Features
The Cancer Knowledgebase is a dynamic digital resource offering rich insights from over 2100 genes, 15,000 clinical trials to clinicians and researchers looking to accelerate their research & discovery, identify suitable interventions and advance patient outcomes.
Insights curated and overseen by our team of scientific experts, the CKB solution provides insights at the gene & variant level, on targeted therapies, unique efficacy evidence, helping connect the divide between diagnosis, treatment and outcomes.
CKB in Action
With CKB BOOST, you can access curated insights on somatic mutations from:
- 2,100+ genes
- 45,000+ variants
- 15,000+ clinical trials
- 4,000+ targeted therapies
Researchers can view annotations on:
- Protein effect
- Variant Navigator, including an interactive map feature enabling users to easily identify variants within an exon/region
- AMP/ASCO classifications
- Approved therapies & therapeutic interventions
- Diagnostic & Prognostic implications
.png)
FAQ
Find answers to all of your Cancer Knowledgebase questions here.
Create an account and see how Mastermind can enhance your research!